.png)
.png)
Latest news from BIA
BioIndustry Association responds to the publication of the United Kingdom Internal Market Bill
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “The BIA welcomes the commitment in the Bill to preserve the UK internal market, aimed at providing certainty for businesses to work and trade freely across the whole of the UK.
Investing in UK biotech has never been more attractive
Biotech stocks have never been a more attractive destination for investors. As traditional sectors continue to suffer with the market disruption brought about by COVID-19, biopharma and healthcare is one of the few economic sectors to have largely escaped the global downturn.
BIA responds to launch of the National Institute for Health Protection (NIHP)
Commenting on the launch of the National Institute for Health Protection (NIHP) Steve Bates OBE, Chief Executive of the U.K. Bioindustry Association said:
£30 million Biomedical Catalyst opens for applications following successful BIA campaign
From today, innovative biotech companies will be able to apply for access to a share of £30 million in grant funding through a relaunched Biomedical Catalyst.
Enesi Pharma’s ImplaVax® Solid-Dose and Needle-Free Vaccination Platform Wins Best New Vaccine Technology/Platform Award at the World Vaccine Congress
Enesi Pharma (“Enesi”) announces that ImplaVax® has won the ‘Best New Vaccine Technology/Platform Award’ at the World Vaccine Congress Washington Virtual annual event (28 September – 1 October 2020). The Vaccine Industry Excellence (ViE) Awards honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress.
RevoluGen Announces the Appointment of Sue Charles to Communications Head
The UK genomic tools developer, RevoluGen Ltd. (‘RevoluGen or the Company), today announces the appointment of Sue Charles as Head of Corporate Communications and Investor Relations.
Synthetic Biology start up NanoSyrinx secures capital to develop its fully customisable platform for intra-cellular engineering
NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space.
CTI Clinical Trial and Consulting Services Announce Dosing of First Subject in Janssen’s ENSEMBLE Phase 3 COVID-19 Vaccine Trial
CTI research site is the lead enroller of the study, with dozens of patients randomized in the first week, and more scheduled for dosing in the next several.
CEO Update|Monday 28 September
Great early news from the BIA Antibody Taskforce project. IONTAS has announced today they’ve identified potent SARS-CoV2 neutralising antibodies that can block COVID-19 infection at doses as low as 20pM in pseudoviral assays and 100pM in live coronavirus assays. The announcement shows just some of the great early work that has developed from the BIA coalition convened by Dr Jane Osbourn OBE, expect more in the coming weeks.
CEO Update|Monday 21 September
Amidst the increasingly concerning picture of rising infection rates in the UK, our sector continues to pioneer long-term solutions to COVID-19. The UK Vaccine Taskforce announced that the Government has secured supply of 60 million doses of Valneva’s COVID-19 vaccine candidate, with options for more between 2022 and 2025. This will be made at Valneva’s UK manufacturing facility in Livingston and the Government is supporting the scale-up of this facility in Scotland. Valneva’s inactivated, adjuvanted, two-dose vaccine candidate is scheduled to enter its first clinical studies this December.
CEO Update|Monday 14 September
The BIA-MHRA Regulatory Innovation Conference will take place this Thursday. Our virtual conference will enable you to listen to MHRA and industry expert speakers, join discussion groups and connect with the wider regulatory community at this pivotal time for medicines regulation in the UK and around the world. Take a look at the programme and register here.
BIA reacts to the International Commission of Heritable Genome Editing Report
Last week a new important report by an international commission of the U.S. National Academy of Medicine, U.S. National Academy of Sciences, and the U.K.’s Royal Society said human embryos whose genomes have been edited should not be used to create a pregnancy until it is established that precise genomic changes can be made reliably without introducing undesired changes — a criterion they assess has not yet been met by any genome editing technology.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
